GEORGE M LEWIS
Architects in Baltimore, MD
License number
Pennsylvania RA014980B
Category
Architects
Type
Registered Architect
Address
Address
2
Baltimore, MD 21209
Pennsylvania
Pennsylvania
Professional information
George Lewis - Baltimore, MD
Work:
M&T Bank
Relationship Banker BB&T Bank - Woodlawn, MD
Relationship Banker Sprint - Towson, MD
Senior Sales Consultant Metris Companies - White Marsh, MD
Customer Service Supervisor Metris Companies - White Marsh, MD
Associate Developer Metris Companies - White Marsh, MD
Retention Representative
Relationship Banker BB&T Bank - Woodlawn, MD
Relationship Banker Sprint - Towson, MD
Senior Sales Consultant Metris Companies - White Marsh, MD
Customer Service Supervisor Metris Companies - White Marsh, MD
Associate Developer Metris Companies - White Marsh, MD
Retention Representative
Education:
Morgan State University, Earl Graves School of Business and Management - Baltimore, MD
Bachelors of Science in Science Business Administration/ Marketing
Bachelors of Science in Science Business Administration/ Marketing
Non-Pyrogenic Derivatives Of Lipid A
US Patent:
6368604, Apr 9, 2002
Filed:
Sep 26, 1997
Appl. No.:
08/938106
Inventors:
David M. Hone - Ellicott City MD
Richard Crowley - Gaithersburg MD
George Lewis - Baltimore MD
Richard Crowley - Gaithersburg MD
George Lewis - Baltimore MD
Assignee:
University of Maryland Biotechnology Institute - Baltimore MD
International Classification:
A61K 3902
US Classification:
4242341, 4242571, 4242581
Abstract:
The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce chemokine secretion, such as MIP-1, but not proinflammatory cytokines, such as TNF, IL-1 and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.
ChemokineâGlycosaminoglycan Complexes And Their Use In Treating Or Preventing Receptor Mediated Diseases
US Patent:
6399078, Jun 4, 2002
Filed:
Jun 1, 1999
Appl. No.:
09/323719
Inventors:
Anthony L. Devico - Alexandria VA
George K. Lewis - Baltimore MD
Jennifer M. Burns - Baltimore MD
Robert Gallo - Bethesda MD
George K. Lewis - Baltimore MD
Jennifer M. Burns - Baltimore MD
Robert Gallo - Bethesda MD
Assignee:
University of Maryland Biotechnology Institute - Baltimore MD
International Classification:
A61K 4700
US Classification:
4242781, 4241851, 4242791, 514 2, 514 56, 514 59, 514885
Abstract:
The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the function or aberrant function of a cell surface receptor.
Treatment And Prevention Of Immunodeficiency Virus Infection By Administration Of Non-Pyrogenic Derivatives Of Lipid A
US Patent:
6841345, Jan 11, 2005
Filed:
Aug 26, 1999
Appl. No.:
09/383709
Inventors:
David M. Hone - Ellicott City MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US
Assignee:
University of Maryland Biotechnology Institute - Baltimore MD
International Classification:
C12Q 170
US Classification:
435 5, 435 72, 435 732, 435 737, 435 41, 43525233, 4242411, 514 54
Abstract:
The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce β chemokine secretion, such as MIP-1β, but not proinflammatory cytokines, such as TNFα, IL-1β and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.
Treatment And Prevention Of Immunodeficiency Virus Infection By Administration Of Non-Pyrogenic Derivatives Of Lipid A
US Patent:
2004012, Jun 24, 2004
Filed:
Dec 10, 2003
Appl. No.:
10/732783
Inventors:
David Hone - Ellicott City MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US
Richard Crowley - Gaithersburg MD, US
George Lewis - Baltimore MD, US
International Classification:
A61K031/739, A61K031/7076, A61K031/7072, A61K038/19
US Classification:
424/085100, 514/054000, 514/046000, 514/050000, 514/220000
Abstract:
The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce chemokine secretion, such as MIP-1, but not proinflammatory cytokines, such as TNF, IL-1 and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.
Method For Introducing And Expressing Genes In Animal Cells And Live Invasive Bacterial Vectors For Use In The Same
US Patent:
5877159, Mar 2, 1999
Filed:
May 3, 1995
Appl. No.:
8/433790
Inventors:
Robert J. Powell - Baltimore MD
George K. Lewis - Baltimore MD
David M. Hone - Ellicott City MD
George K. Lewis - Baltimore MD
David M. Hone - Ellicott City MD
Assignee:
University of Maryland at Baltimore - Baltimore MD
International Classification:
A01N 4304, A61K 3170, C12N 1563
US Classification:
514 44
Abstract:
A method for introducing and expressing genes in animal cells is disclosed comprising infecting said animal cells with live invasive bacteria, wherein said bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e. g. , a vaccine antigen, an therapeutic agent, an immunoregulatory agent or a anti-sense RNA or a catalytic RNA.
Non-Destructive Method To Quantify And Isolate Antigen-Specific B Cells And Uses Thereof
US Patent:
2010018, Jul 29, 2010
Filed:
Mar 26, 2008
Appl. No.:
12/593037
Inventors:
George K. Lewis - Baltimore MD, US
Anthony L. Devico - Alexandria VA, US
Robin Flinko - Chester MD, US
Anthony L. Devico - Alexandria VA, US
Robin Flinko - Chester MD, US
International Classification:
A61K 35/12, G01N 33/53
US Classification:
424 9371, 435 724
Abstract:
The present invention relates to antigen-Ig Ab fusion molecules and methods of using same, wherein antigen-Ig Ab fusion molecules include an antigen fused to an immunoglobulin molecule, fragment or variant thereof and wherein the fusing of the immunoglobulin molecule to the antigen does not alter the specificity or tertiary structure of important epitopes of the antigen. This method allows the direct quantification and isolation of antigen-specific B cells by flow cytometry in essentially any species.
Constrained Hiv Envelope-Based Immunogen That Simultaneously Presents Receptor And Coreceptor Binding Sites
US Patent:
2010022, Sep 2, 2010
Filed:
Jul 6, 2006
Appl. No.:
11/994870
Inventors:
Anthony L. DeVico - Alexandria VA, US
George Lewis - Baltimore MD, US
Lai-Xi Wang - Ellicott City MD, US
George Lewis - Baltimore MD, US
Lai-Xi Wang - Ellicott City MD, US
Assignee:
UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE - Baltimore MD
International Classification:
A61K 39/395, C07K 14/00, A61K 39/00, A61P 31/18, A61P 37/04
US Classification:
4241301, 530324, 4241851
Abstract:
The present invention relates to a soluble binding complex comprising a soluble gp120 trimer, in which only two gp120 protomers have CD4 binding sites occupied by interconnecting CD4 mimetic moieties, thereby allowing for the exposure of CD4-induced epitopes on the mimetic-bound protomers and an unoccupied CD4 binding site on the third gp120 protomer.
Method For Introducing And Expressing Genes In Animal Cells, And Live Invasive Bacterial Vectors For Use In The Same
US Patent:
6150170, Nov 21, 2000
Filed:
Jul 30, 1998
Appl. No.:
9/126220
Inventors:
Robert J. Powell - Baltimore MD
George K. Lewis - Baltimore MD
David M. Hone - Ellicott City MD
George K. Lewis - Baltimore MD
David M. Hone - Ellicott City MD
Assignee:
University of Maryland at Baltimore - Baltimore MD
International Classification:
C12N 1563, C12N 1500, C12N 500, A01N 4304, A61K 3170
US Classification:
435455
Abstract:
A method for introducing and expressing genes in animal cells is disclosed comprising infecting said animal cells with live invasive bacteria, wherein said bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e. g. , a vaccine antigen, an therapeutic agent, an immunoregulatory agent or a anti-sense RNA or a catalytic RNA.
General Method For Generating Human Antibody Responses In Vitro
US Patent:
2010032, Dec 23, 2010
Filed:
May 11, 2007
Appl. No.:
12/300461
Inventors:
George K. Lewis - Baltimore MD, US
Yongjun Guan - Abingdon MD, US
Yongjun Guan - Abingdon MD, US
International Classification:
C12P 21/08, G01N 33/50, C12N 5/0786, C12N 5/078, C12N 5/0783
US Classification:
435 711, 435 724, 435404, 435406
Abstract:
This invention relates to an in vitro method of producing antigen specific B cells and antibodies that provides for the capture of an entire primary human antibody repertoire for any foreign antigen, allows for screening large numbers of immunogen/adjuvant combinations, and permits the isolation of human monoclonal antibodies on demand thereby obviating the need to immunize humans with the target antigen.